Lindsey Rolfe
Director/Board Member bij ATRECA, INC.
Vermogen: - $ op 29-02-2024
Profiel
Lindsey Rolfe is on the board of Atreca, Inc. and CERo Therapeutics Holdings, Inc. and Member of The Royal College of Physicians.
She previously was Chief Medical Officer & Executive VP-Clinical at Clovis Oncology, Inc.
Dr. Rolfe received a doctorate from The University of Edinburgh.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
ATRECA, INC. CLASS A
-.--% | 13-06-2023 | 0 ( -.--% ) | - $ | 29-02-2024 |
Actieve functies van Lindsey Rolfe
Bedrijven | Functie | Begin |
---|---|---|
ATRECA, INC. | Director/Board Member | 22-08-2019 |
The Royal College of Physicians | Corporate Officer/Principal | - |
Eerdere bekende functies van Lindsey Rolfe
Bedrijven | Functie | Einde |
---|---|---|
CLOVIS ONCOLOGY, INC. | Chief Tech/Sci/R&D Officer | 01-06-2023 |
Opleiding van Lindsey Rolfe
The University of Edinburgh | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
ATRECA, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Clovis Oncology, Inc.
Clovis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO. | Health Technology |